MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, announced today that David Kaysen, President and CEO, and
Medi Jiwani, Vice President and CFO,
will present the Company's business strategy and financial results
at the 11th Annual JMP Securities Research Conference at
12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in
San Francisco.
Attendance at the conference is by invitation only. A live audio
webcast of the presentation will be broadcast via the Internet.
Those interested in listening to the webcast may access it at
http://wsw.com/webcast/jmp17/upi/, or through Uroplasty's website
at www.uroplasty.com. An archived replay of the presentation will
be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
medical device company that develops, manufactures and markets
innovative proprietary products for the treatment of voiding
dysfunctions. Our focus is the continued commercialization of our
Urgent® PC Neuromodulation System, the only FDA-cleared
neuromodulation system that delivers posterior tibial nerve
stimulation (PTNS) for the office-based treatment of overactive
bladder and associated symptoms of urgency, frequency and urge
incontinence. We also offer Macroplastique® Implants, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For
Further Information:
|
|
Uroplasty,
Inc.
|
EVC
Group
|
David
Kaysen, President and CEO, or
|
Doug
Sherk/Jenifer Kirtland (Investors), 415.568.9349
|
Medi
Jiwani, Vice President, CFO, Treasurer
|
Chris Gale
(Media), 646.201.5431
|
952.426.6140
|
|
SOURCE Uroplasty, Inc.